NASDAQ:DNLI - Denali Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $36.30
  • Forecasted Upside: -15.15 %
  • Number of Analysts: 12
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
$42.78
▼ -2.78 (-6.10%)
1 month | 3 months | 12 months
Get New Denali Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DNLI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DNLI

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$36.30
▼ -15.15% Downside Potential
This price target is based on 12 analysts offering 12 month price targets for Denali Therapeutics in the last 3 months. The average price target is $36.30, with a high forecast of $50.00 and a low forecast of $20.00. The average price target represents a -15.15% upside from the last price of $42.78.
Buy
The current consensus among 12 polled investment analysts is to buy stock in Denali Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/9/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/7/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/5/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/3/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
5/3/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings
8/1/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/30/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 3 hold ratings
  • 0 sell ratings
10/30/2020

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 3 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/16/2020WedbushBoost Price TargetPositive ➝ Outperform$39.00 ➝ $50.00High
i
10/16/2020BTIG ResearchDowngradeBuy ➝ NeutralHigh
i
9/14/2020JPMorgan Chase & Co.Initiated CoverageOverweight$35.00High
i
8/24/2020Morgan StanleyBoost Price TargetOverweight$28.00 ➝ $45.00Medium
i
8/20/2020HC WainwrightReiterated RatingBuy$28.00 ➝ $45.00Medium
i
8/10/2020WedbushReiterated RatingOutperformMedium
i
Rating by L. Chico at Wedbush
5/13/2020NomuraReiterated RatingBuy$35.00Low
i
4/15/2020Morgan StanleyLower Price TargetOverweight$30.00 ➝ $28.00High
i
3/18/2020Cantor FitzgeraldReiterated RatingNeutralMedium
i
Rating by C. Duncan at Cantor Fitzgerald
3/13/2020Evercore ISIUpgradeIn-Line ➝ Outperform$20.00High
i
3/9/2020Nomura SecuritiesReiterated RatingBuy$35.00Low
i
Rating by Christopher Marai at Nomura Securities
2/28/2020WedbushUpgradeNeutral ➝ Outperform$24.00Low
i
Rating by L. Chico at Wedbush
2/24/2020Jefferies Financial GroupInitiated CoverageBuy$35.00High
i
2/18/2020Stifel NicolausInitiated CoverageHold$26.00Low
i
1/26/2020The Goldman Sachs GroupUpgradeNeutral ➝ Buy$20.00 ➝ $37.00High
i
12/20/2019HC WainwrightReiterated RatingBuy$28.00Medium
i
Rating by Andrew Fein at HC Wainwright
9/25/2019WedbushInitiated CoverageNeutral$19.00 ➝ $19.00High
i
Rating by L. Chico at Wedbush
9/13/2019Nomura SecuritiesInitiated CoverageBuy$35.00High
i
8/9/2019Morgan StanleySet Price TargetBuy$32.00Low
i
Rating by Matthew Harrison at Morgan Stanley
8/9/2019BTIG ResearchInitiated CoverageBuy ➝ Buy$30.00High
i
8/8/2019HC WainwrightReiterated RatingBuyMedium
i
Rating by Andrew Fein at HC Wainwright
7/15/2019HC WainwrightSet Price TargetBuy$28.00High
i
Rating by Andrew Fein at HC Wainwright
6/26/2019HC WainwrightInitiated CoverageBuy ➝ Buy$28.00Medium
i
Rating by A. Fein at HC Wainwright
1/29/2019Cantor FitzgeraldDowngradeOverweight ➝ Neutral$25.00High
i
Rating by Charles Duncan at Cantor Fitzgerald
12/7/2018Cantor FitzgeraldReiterated RatingBuy$25.00High
i
Rating by Charles Duncan at Cantor Fitzgerald
11/14/2018Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$25.00High
i
Rating by C. Duncan at Cantor Fitzgerald
11/12/2018Janney Montgomery ScottInitiated CoverageBuy ➝ Buy$26.00Low
i
1/2/2018Evercore ISIInitiated CoverageOutperform ➝ Outperform$23.00Medium
i
1/2/2018The Goldman Sachs GroupInitiated CoverageNeutral ➝ NeutralHigh
i
1/2/2018Morgan StanleyInitiated CoverageOverweight ➝ Overweight$25.00High
i
1/2/2018JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$24.00High
i
(Data available from 10/31/2015 forward)
Denali Therapeutics logo
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease. It is also developing receptor interacting serine/threonine protein kinase 1 (RIPK1) product candidates, such as DNL747, a selective and brain-penetrant small molecule RIPK1 inhibitor product candidate that is in Phase 1b clinical trial for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). In addition, the company develops enzyme transport vehicle: iduronate 2-sulfatase, an enzyme replacement therapy program for MPS II, a lysosomal storage disorder; antibody transport vehicle (ATV): alpha-synuclein (aSyn) program, a protein that spreads throughout the brain in Parkinson's disease; ATV: triggering receptor expressed in myeloid cells 2, a therapeutic candidate designed to rescue microglial function in Alzheimer's disease; and ATV: Tau, a therapeutic targeting the spreading of Tau. Further, it is developing LF1, an undisclosed large molecule program to treat neurodegenerative diseases. Additionally, the company has various seed programs under the research, discovery, and preclinical stages of development. Denali Therapeutics Inc. has collaboration agreement with Takeda Pharmaceutical Company and Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is based in South San Francisco, California.
Read More

Today's Range

Now: $42.78
$42.14
$45.38

50 Day Range

MA: $39.12
$31.99
$46.14

52 Week Range

Now: $42.78
$12.39
$47.17

Volume

510,034 shs

Average Volume

641,574 shs

Market Capitalization

$4.53 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.82